Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Abstract Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ana Fernández Montes, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Francisca Vázquez Rivera, Nieves Martinez Lago, Marta Covela Rúa, Antía Cousillas Castiñeiras, Paula Gonzalez Villarroel, Juan De la Cámara Gómez, José Carlos Méndez Méndez, Carmen Carriles Fernández, Manuel Sanchez Cánovas, Teresa Garcia García
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/79955248229f4b8ab9ff4d86bc53b994
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/79955248229f4b8ab9ff4d86bc53b994

Ejemplares similares